



PATENT
ATTORNEY DOCKET NO. INTEL1270-1 (P18602)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Berlin et al.	Art Unit:	1634
Application No.:	10/750,315	Examiner:	Crow, Robert Thomas
Filed:	December 30, 2003	Conf. No.:	1701
Title:	NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF UPTAKE OF NUCLEOTIDES DURING MOLECULAR REPLICATION		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

TERMINAL DISCLAIMER

Sir:

The undersigned attorney of record for Petitioner, INTEL CORPORATION, INC., a corporation with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, represents that Petitioner is the Owner of 100 percent interest in Application No. 10/750,315, filed December 30, 2003, entitled NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF UPTAKE OF NUCLEOTIDES DURING MOLECULAR REPLICATION, as evidenced by the Assignment recorded in the United States Patent and Trademark Office on August 3, 2004, at Reel 015638, Frame 0592.


06/19/2006 SSITHIB1 00000012 10750315

01 FC:1814

130.00 OP

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on June 14, 2006, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Adam Wentzel

June 14, 2006

In re Application of:

Berlin et al.

Application No.: 10/750,315

Filed: December 30, 2003

Page 2

PATENT

Attorney Docket No.: INTEL1270-1(P18602)

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 11/329,693, entitled METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING.

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 11/255,386, entitled NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF MOLECULAR DECONSTRUCTION.

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 11/235,796, entitled METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING.

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 10/886,400, entitled NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF UPTAKE OF PRECURSORS DURING MOLECULAR REPLICATION.

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 10/886,094, entitled NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF UPTAKE OF PRECURSORS DURING MOLECULAR REPLICATION.

In re Application of:

Berlin et al.

Application No.: 10/750,315

Filed: December 30, 2003

Page 3

PATENT

Attorney Docket No.: INTEL1270-1(P18602)

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 10/660,902, entitled METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING.

The undersigned attorney of record further represents that INTEL CORPORATION, INC., a corporation, with its place of business at 2200 Mission College Boulevard, Santa Clara, California 95052, is the Owner of 100 percent interest in U.S. Patent Application No. 09/962,255, issued as U.S. Patent No. 6,982,165, entitled NUCLEIC ACID SEQUENCING BY RAMAN MONITORING OF MOLECULAR DECONSTRUCTION.

The evidentiary documents referred to herein have been reviewed by the undersigned and it is certified that to the best of the undersigned's knowledge and belief, title is in the Owners as set forth above.

Pursuant to 37 C.F.R. § 1.321(c), the undersigned, on behalf of Petitioner, INTEL CORPORATION, INC., disclaims the terminal part of any patent granted on the above-identified Application No. 10/750,315 that would extend beyond the expiration date of a patent granted on U.S. Patent Application Nos. 11/329,693; 11/255,386; 11/235,796; 10/886,400; 10/886,094; 10/660,902 and issued patent 6,982,165. Petitioner hereby agrees that any patent so granted on the above-identified application No. 10/750,315 shall be enforceable only for and during such period that said patent and a patent granted on U.S. Patent Application Nos. 11/329,693; 11/255,386; 11/235,796; 10/886,400; 10/886,094; 10/660,902 and issued U.S. Patent No. 6,982,165 are commonly owned, this Agreement to run with any patent granted on the above-identified application and to be binding upon the grantees, its successor or assigns.

✓ In re Application of:

Berlin et al.

Application No.: 10/750,315

Filed: December 30, 2003

Page 4

PATENT

Attorney Docket No.: INTEL1270-1(P18602)

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and believe are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

In re Application of:

Berlin et al.

Application No.: 10/750,315

Filed: December 30, 2003

Page 5

PATENT

Attorney Docket No.: INTEL1270-1(P18602)

Enclosed is a check in the amount of \$130.00 for the Terminal Disclaimer Fee. No other fees are deemed necessary with the filing of this paper. However, the Commissioner is hereby authorized to charge for any other fees that may be associated with this communication, or credit any overpayment, to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A copy of the Transmittal Sheet is enclosed.

Respectfully submitted,

Date: June 14, 2006

Lisa A. Haile Reg No 38729
for Lisa A. Haile, J.D., Ph.D.

Registration No.: 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP

ATTORNEYS FOR INTEL CORPORATION

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

USPTO Customer No.: 28213